Cardiovascular drug may improve heart failure and help prevent sudden death

November 16, 2005

NEW YORK - Nov. 16, 2005 - Research shows that Carvedilol, a cardiovascular drug, could be useful in reducing cardiac death in high risk patients with prior myocardial infarction and/or heart failure and also in reducing the incidence and/or preventing the occurrence of atrial fibrillation in a number of clinical situations. A review of this research is published in the journal Pacing and Clinical Electrophysiology.

Carvedilol possesses electrophysological properties that affect a variety of ionic currents that may result in a significant anti-arrhythmic action. Compared to other drugs in the same class, researchers say Carvedilol may have the right combination of pharmacological properties to reduce cardiac death, and reduce or prevent the incidence of atrial fibrillation, a major disorder of the cardiac rhythm. Future confirmation of this position could change the way physicians manage patients at high risk for sudden cardiac death.

Currently, the only effective management of these patients is to implant a device known as an implantable cardiovertor defibrillator (ICD). The device can automatically detect an abnormal rhythm and deliver an electric shock to restore normal heart rhythm. Unfortunately, the device has several side effects that reduce the patient's quality of life and is extremely costly. Only a fraction of those patients who may be deemed eligible for such a device will receive it.

According to the American Heart Association's Heart Disease and Stroke Statistics 2005 update, over 70,000,000 Americans have one or more types of cardiovascular disease; over seven million have suffered from myocardial infarction.
-end-
This study is published in Pacing and Clinical Electrophysiology. Media who wish to receive a PDF of this article may contact medicalnews@bos.blackwellpublishing.net.

Corresponding author, Nabil El-Sherif, MD is available for questions and interviews. He can be reached on the weekdays at (917) 684-7970 or nelsherif@aol.com. Dr. El-Sherif is an acknowledged national and international expert in the field of disorders of the cardiac rhythm and is currently Director of the Cardiology division at the New York Harbor VA Healthcare System.

About the Journal
Pacing and Clinical Electrophysiology (PACE) is the foremost peer-reviewed journal in the field of pacing and implantable cardioversion defibrillation, publishing over 50% of all English language articles in its field, featuring original, review, and didactic papers, and case reports related to daily practice. Articles also include editorials, book reviews, Musings on humane topics relevant to medical practice, electrophysiology (EP) Rounds, NASPE-Heart Rhythm Society policy statements and information concerning the quality of devices used in the practice of the specialty.

About Blackwell Publishing
Blackwell Publishing is the world's leading society publisher, partnering with more than 600 academic and professional societies. Blackwell publishes over 750 journals annually and, to date has published close to 6,000 text and reference books, across a wide range of academic, medical, and professional subjects.

Blackwell Publishing Ltd.

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.